SHIKARI® Q-INFLIXI
The Matriks Biotek SHIKARI® Infliximab-Remicade ELISA has been specially developed for the quantitative analysis of free Infliximab in serum and plasma samples.
SHIKARI® Q-ATI
Required Volume 
Total Time 
Sample
Sample Number
Detection Limit 
Spike Recovery 
Shelf Life
10ul
70 min
Serum, plasma
96
30ng/mL
85-115%
1 year
The use of Infliximab (Remicade) has been linked to the development of antibodies against the drug at various levels (in some cases to the point of neutralizing the treatment), possibly leading to severe complications. The SHIKARI® Q-ATI ELISA Kit provides a tool for easily monitoring anti-Infliximab levels and exploring ways of limiting problematic immunoresponses to this drug.
Calibration Curve
SHIKARI® Q-INFLIXI & Q-ATI
Infliximab (Remicade®)
Enzyme immunoassay for the quantitative determination of free Infliximab (Remicade®) in serum and plasma
Enzyme immunoassay for the determination of specific antibodies to infliximab in human serum and plasma with confirmation.
Required Volume 
Total Time 
Sample
Sample Number
Detection Limit 
Spike Recovery 
Shelf Life
20ul
140 min
Serum, plasma
96
15ng/ml
85-115%
1 year
Q-INFLIXIv2: $878.00                                        Lead time: 1-2 weeks
Q-ATIv5 (w/o Confirmation): $878.00
Q-ATIv6 (w/ Confirmation)  : $943.00            
Calibration Curve
Q-ATIv5


Q-ATIv6
Peer Reviewed Journals:

Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016.**

Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver. Sep 9 2016.**

Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr. Jun; 19(2): 116–122, 2016.**

Hayashi S, et al., Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther (2016) 3:155–166 **

Al-Karkhi M.A., et al., Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences, Volume 14, Issue 11 Ver. IV (Nov. 2015), PP 95-100.**

Al-Karkhi M.A., et al., Development of Antibodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad, 57: (241-243), 2015.**

Pallagi-Kunstár É. et al., Utility of serum TNF-a, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol. 20(17): (5031-5035), 2014. **

Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology & Hepatology, August (478-489),2014. **

Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn’s disease, Gut 0:1–9, 2013. **

Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease, J Crohns Colitis 2013. **

Bortlik M, et al, Infliximab trough levelsmay predict sustained response to infliximab in patients with Crohn's disease, Journal of Crohn's and Colitis 2012. **

 Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases, Autoimmun Highlights, 2012. **

Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology 2012; 39: 1- 4. **

Seok Lee Y, et al, “Efficacy of Early Infliximab Treatment for Pediatric Crohn’s Disease: A Three-year Follow-up”, Pediatric Gastroenterology, Hepatology & Nutrition 2012; 15(4):243-249 **


** Open Access 
.....................................................
Lead time: 1-2 weeks
.....................................................
Drug Measurement
Anti-drug Antibody Measurement
Quantitative
Quantitative
Qualitative
Semi-Quantitative
Infliximab (Remicade®)
Anti TFN-alpha Blockers
Q-INFLIXI
(Free)

#TR-Q-INFLIXIv2
Q-ATIv5
(Free)

#TR-ATIv5
Q-ATIv8 DUO
(Free & Total)

#TR-ATIv8
Q-ATIv6
(Free, Specific)

#TR-ATIv6
Iwai North America Inc.

541 Taylor Way Suite# 4
 San Carlos, CA 94070
 Phone : (650) 486-1541
Fax : (650) 394-8638
 Open weekdays 9 AM-6 PM (PST)
.........................................................................................................................................................................................................................................................
SHIKARI® Q-ATI DUO
Free and Total Anti drug Antibody monitoring have recently gained high importance along with measuring free drug from the patient samples. In order to make these measurements simple yet more informative, Matriks has produced SHIKARI® Q-ATI DUO to measure Free and Total anti drug antibodies to Infliximab simultaniously on the same plate. The kit is semi-quantitative and enables follow up of the patients to adjust the dose of the drug and/or frequency of administration
Enzyme immunoassay for the semi-quantitative determination (screening) of total and free antibodies to infliximab in serum and plasma.
Required Volume 
Total Time 
Sample
Sample Number
Detection Limit 
Spike Recovery 
Shelf Life
10ul
95 min
Serum, plasma
96
156ng/ml
  -
1 year
Q-ATIv8 (DUO): $943.00

Q-ATIv8

Lead time: 1-2 weeks